|Bid||2.70 x 1000|
|Ask||2.91 x 900|
|Day's Range||2.7300 - 3.1500|
|52 Week Range||2.2500 - 17.1200|
|Beta (3Y Monthly)||3.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 26, 2017 - Oct 30, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.33|
Travis CI, the popular Berlin-based open-source continuous integration service, has been acquired by Idera, a company that offers a number of SQL database management and administration tools for both on-premises and cloud applications. The move comes at a time when other continuous integration services, including the likes of Circle CI, seem to be taking market share away from Travis CI. Idera, which itself is owned by private equity firm TA Associates, says that Travis is complementary to its current testing tools business and that the acquisition will benefit its current customers.
Vinnie, Vin Milano became the CEO of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) in 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After Read More...
Idera Pharmaceuticals, Inc. (IDRA) today announced that the company will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco. An archived version will also be available on the company’s website after the event for 90 days. As a convenience to investors, a copy of the company’s presentation will be posted on the Idera corporate website at 7:30 a.m. Eastern Time on Monday, January 7, 2019.
NEW YORK, NY / ACCESSWIRE / December 17, 2018 / Both Johnson & Johnson and Idera Pharmaceuticals were big losers in Friday’s trading session. J&J tumbled on a Reuters story that alleged it knew about its baby powder having asbestos for decades while Idera announced data from an ongoing phase 2 trial that were actually encouraging. Johnson & Johnson shares were tanking on Friday, on a Retuers story that the company had known for decades that its baby powder has asbestos.
Idera Pharmaceuticals, Inc. (IDRA) today is presenting data from the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with ipilimumab (Yervoy®*).
Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs, today announced that it plans to release an update on clinical data from the ongoing Phase 2 trial of the combination of intratumoral tilsotolimod and ipilimumab for unresectable or metastatic melanoma following failure of anti-PD-1 inhibitor treatment prior to the opening of the U.S. financial markets on Friday, December 14, 2018. To participate in the conference call, please dial (844) 882-7837 (domestic) and (574) 990-9824 (international). The webcast can be accessed live or in archived form in the “Investors” section of the company’s website at www.iderapharma.com. The company will be posting a slide presentation to the Idera corporate website in the “Investors” section which will be referenced during the conference call.
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Biotech stocks pulled back in last week. Incidentally, some large-cap biotech stocks were hitting new peaks even amid the sectoral downturn. New molecular entity approval hit a new peak at 55 thus far ...
If you want to know who really controls Idera Pharmaceuticals Inc (NASDAQ:IDRA), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more Read More...
Idera (IDRA) delivered earnings and revenue surprises of 17.86% and -93.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Exton, Pennsylvania-based company said it had a loss of 43 cents. Losses, adjusted for gains related to mergers and acquisitions, were 46 cents per share. The results surpassed ...
Idera Pharmaceuticals Inc (NASDAQ:IDRA), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is IDRARead More...
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Portola Pharmaceuticals were deep in the red on Thursday after reporting second quarter results that revealed revenue and earnings miss. Idera Pharmaceuticals shares were rising after announcing that the company would be a part of a fireside chat in NYC next week. The company also reported second quarter results last week that revealed a positive earnings surprise.